Recent

% | $
Quotes you view appear here for quick access.

XOMA Corporation Message Board

  • gates_wanabe gates_wanabe Nov 20, 2012 4:29 PM Flag

    XOMA985 will have sales over 1.2 billion in a year.

    The inferior sister drug called Exforge has sales of 1.2 billion. John Varian said Xoma985 had superior trial results. Xoma expects sales greater than Exforge. Xoma said they will license the drug. Xoma WILL get over a billion for it. The stock should go well over 30 a share.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hi Gypsum. I don't know the answers. I'm wondering if it has an effect on the eye problems that diabetics have? That would be sweet.

      Sentiment: Strong Buy

      • 1 Reply to gfhammond1996
      • Diabetic macular edema affects up to 30% of people who have had diabetes for 20 years or more, and if untreated, 20 to 30% of people who have it will experience moderate visual loss.

        Check out Lucentis for diabetic macular edema. It is a monoclonal antibody. Pretty bad side effects. I doubt they have orphan status because of the above paragraph patient population. Also, it affects the back of the eye. I would bet anything 052 would work. However, must be a pretty good reason xoma didn't go after this indication UNLESS it is going to be POC #3! (INsert wishful thinking here).
        -------------------------------------------------------------------------------------------------------------------

        LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with diabetic macular edema (DME).

        What important safety information should I know about LUCENTIS?

        LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious infections inside the eye. You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients.

        Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes.

        Some patients have had increased eye pressure within 1 hour of an injection.

        Serious side effects include inflammation inside the eye and, rarely, problems related to the injection procedure, such as cataracts. These side effects can make your vision worse.

        The most common eye-related side effects are increased redness in the white of the eye, cataract, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, and nausea.

        If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.

    • I sure got that one wrong. I thought the stock would open over 10 dollars. Only with Xoma can a company announce positive phase3 results and the stock does nothing. If it was Pfizer the stock would have gone up significantly. Or any other company for that matter.

    • That's not all that's gonna get bigger if all this is true! :) God, the years of foreplay we have had to endure.

      Sentiment: Buy

    • Solid news.....this wasn't expected until Q1 of next year.

      Another surprise announcement tomorrow would easily burn up a few million shorts!

      Sentiment: Strong Buy

      • 2 Replies to watcherpast
      • This news is way ahead of schedule. It follows that the NDA filing may have already taken place as well. I have always thought the 6 week trial that began sometime prior to march 2012 could have been finished in a few months and filed shorty after. Xoma has said as much. This explains the GE loan. Xoma can take on a high interest loan since a cash windfall is coming with the license fee. There is no shortage of Big Pharma companies that want to add a blockbuster to their pipeline. Xoma has patents for a dozen years. This is wonderful. Kudo's to Xoma's management.

      • Help us out please guys. This is the first of 3 FDCs studies that Xoma was going to run using perindopril right? What I'm curious about is did they contribute any science or was it a clever guess that it would work. Reckon they'll be able to benefit from Servier's sales of this product in the other 91 countries? Both drugs are available at very low generic prices. I guess we'll find out tomorrow if it's a big deal or not.

        Sentiment: Buy

 
XOMA
0.5689+0.1146(+25.23%)2:16 PMEDT